This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 1
  • /
  • HSR clearance for expansion of Innate Pharma colla...
News

HSR clearance for expansion of Innate Pharma collaboration with Sanofi on NK cell engagers

Read time: 1 mins
Published:25th Jan 2023

Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective

As announced on December 19, 2022, Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Under the terms of the agreement, Innate will receive €25 million upfront payment and up to €1.35 billion total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.